Genmab — Maj 2023
-
Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA
(teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) https://www.businesswire.com/news/home/20230427005964/en/Horizon-Therapeutics-plc-Announces-Initiation-of-Phase-3-Clinical-Trial-in-Japan-Evaluating-TEPEZZA-teprotumumab-trbw-in-Adults-with-ChronicLow-Clinical-Activity-Score-CAS-Thyroid-Eye-Disease-TED -
-
-
Shortpositioner på danske aktier https://www.proinvestor.com/boards/112386
-
Antibody Architects https://www.youtube.com/watch?v=Yh9SInylMvk
-
Genmab vil blive presset hvis CART virkelig vil få et større patientgrundlag end det ser ud til lige nu. JNJ ligner nogen der tror lidt på det https://finance.yahoo.com/news/johnson-johnson-ignites-car-t-181429711.html
-
Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
05/03/23 -- TEPEZZA (teprotumumab-trbw) Net Sales of $405.3 Million -- https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-reports-first-quarter-2023-financial -
Jo, men: More recently, the Company has seen the expansion drive positive momentum in the business, including increases in new prescribers, patient enrollment forms and patient starts. As new prescribers and patients work through the reimbursement process, the Company expects a more meaningful impact to net sales later in the year.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind